Penumbra, Inc. (NYSE:PEN) Director Arani Bose Sells 20,000 Shares

Penumbra, Inc. (NYSE:PENGet Rating) Director Arani Bose sold 20,000 shares of Penumbra stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $250.25, for a total transaction of $5,005,000.00. Following the sale, the director now owns 445,662 shares of the company’s stock, valued at $111,526,915.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Penumbra Trading Down 1.9 %

PEN stock traded down $4.74 during midday trading on Wednesday, hitting $238.86. The stock had a trading volume of 319,405 shares, compared to its average volume of 334,301. The company’s 50-day moving average price is $220.08 and its 200 day moving average price is $186.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.23 and a quick ratio of 2.92. The firm has a market cap of $9.07 billion, a PE ratio of -291.29 and a beta of 0.48. Penumbra, Inc. has a 12-month low of $114.86 and a 12-month high of $253.22.

Penumbra (NYSE:PENGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. The business had revenue of $213.68 million during the quarter, compared to the consensus estimate of $212.41 million. Penumbra had a positive return on equity of 0.45% and a negative net margin of 3.68%. On average, equities research analysts predict that Penumbra, Inc. will post 0.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. TheStreet upgraded Penumbra from a “d+” rating to a “c-” rating in a research report on Friday, January 13th. Canaccord Genuity Group decreased their price objective on shares of Penumbra from $203.00 to $185.00 and set a “buy” rating on the stock in a research report on Friday, November 4th. BTIG Research raised their target price on shares of Penumbra from $204.00 to $240.00 and gave the company a “buy” rating in a report on Monday, December 5th. Truist Financial lifted their target price on shares of Penumbra from $228.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday, December 20th. Finally, Wells Fargo & Company lifted their price objective on Penumbra from $225.00 to $255.00 and gave the stock an “overweight” rating in a research report on Monday, December 12th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $238.55.

Institutional Trading of Penumbra

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PEN. Captrust Financial Advisors boosted its position in shares of Penumbra by 44.1% in the second quarter. Captrust Financial Advisors now owns 219 shares of the company’s stock worth $27,000 after acquiring an additional 67 shares during the last quarter. WASHINGTON TRUST Co purchased a new position in Penumbra during the second quarter worth approximately $31,000. Hanseatic Management Services Inc. acquired a new position in shares of Penumbra in the 3rd quarter valued at $35,000. Wipfli Financial Advisors LLC purchased a new stake in shares of Penumbra during the 3rd quarter valued at $40,000. Finally, Fifth Third Bancorp increased its holdings in shares of Penumbra by 30.4% during the 4th quarter. Fifth Third Bancorp now owns 223 shares of the company’s stock worth $50,000 after buying an additional 52 shares during the last quarter. Hedge funds and other institutional investors own 82.42% of the company’s stock.

About Penumbra

(Get Rating)

Penumbra, Inc engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. Its target markets include interventional neuroradiologists, neurosurgeons, neurologists, cardiologists, radiologists, and vascular surgeons.

Read More

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.